<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092594</url>
  </required_header>
  <id_info>
    <org_study_id>21JGD-COVIDM</org_study_id>
    <nct_id>NCT05092594</nct_id>
  </id_info>
  <brief_title>Prognostic Value of IgM in Covid-19 Infection</brief_title>
  <acronym>COVID-M</acronym>
  <official_title>The Prognostic Value of IgM in Covid-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the research is to study the relation between the presence and /or&#xD;
      the anti SARS-Co-V-2 IgM level in an early stage of COVID-19 infection, and the evolution of&#xD;
      the illness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective is to determinate in what manner response of IgM anti-SARS-Co-V-2&#xD;
      relates to patient's immunity statute, in regards to the other so-called humain &quot;seasonal&#xD;
      coronavirus&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Absence of hospitalization versus hospitalization without ventilation during SARS-CoV-2 infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Non ventilation versus ventilation during Covid-19 hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization at Ambroise Paré hospital</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Hospitalization at Ambroise Paré hospital during SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenotherapy</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Use of high-flow oxygenotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Ventilation during SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thoracic CT</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Thoracic CT result during SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's vital statute</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Death of hospitalized patients in Ambroise Paré hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgM anti-SARS-Co-V-2 presence</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>IgM anti-SARS-Co-V-2 level</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling between day 1 to day 14 from first syndromes of Covid-19 infection. Serum or&#xD;
      plasma conservations.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult SARS-CoV-2 positive patients who have blood sampling between 1 day and 14 days from&#xD;
        the first clinical syndromes and their collections of serum or plasma are accessible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years;&#xD;
&#xD;
          -  Have been diagnosed positive of SARS-CoV-2 in the Virological Laboratory of Ambroise&#xD;
             Paré hospital;&#xD;
&#xD;
          -  Have been blood sampled between 1 day and 14 days from the first clinical syndromes,&#xD;
             and their collections of serum or plasma are conserved and accessible;&#xD;
&#xD;
          -  Affiliated to the social security scheme or entitled;&#xD;
&#xD;
          -  Informed and non-opposed to participating to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of patient to participation to the study;&#xD;
&#xD;
          -  Foreign patients under french AME scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Gaillard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microbiological Laboratory - CHU Ambroise Paré - APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis Gaillard, MD, PhD</last_name>
    <phone>+ 33 (0)1 49 09 55 40</phone>
    <email>jean-louis.gaillard@aphp.fr</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>anti SARS-Co-V-2 IgM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

